Cardio Diagnostics Holdings Inc. Company Profile
NASDAQ: CDIOHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Cardio Diagnostics at a glance
Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is a Biotechnology: In Vitro & In Vivo Diagnostic Substances company in the Health Care sector headquartered in Chicago, IL. Cardio Diagnostics is led by Dr. Meeshanthini V. Dogan Ph.D. and employs about 15 people. The company's shares have traded publicly since 2022.
At a market capitalization of $4.8 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001870144, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Cardio Diagnostics do?
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Business description based on the company's public filings.
Company information
- Legal name
- Cardio Diagnostics Holdings Inc.
- Ticker
- NASDAQ: CDIO
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Dr. Meeshanthini V. Dogan Ph.D.
- Employees
- 15
- Headquarters
- 311 West Superior Street, Chicago, IL, United States
- Phone
- 855 226 9991
- Website
- cdio.ai
- IPO year
- 2022
- Market cap
- $4.82M
- SEC CIK
- 0001870144
- Latest annual report
- 10-K · Mar 13, 2026
Companies similar to Cardio Diagnostics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BMRABiomerica Inc. | 1.08 | -0.92% | $4.97M | vs CDIO |
| TRIBTrinity Biotech plc ADR | 6.24 | +13.76% | $5.07M | vs CDIO |
| VNRXVolitionRX Limited | 0.1621 | -1.58% | $5.85M | vs CDIO |
| QCLSQ/C Technologies Inc. | 0.2784 | -6.01% | $2.40M | vs CDIO |
| VRAXVirax Biolabs Group Limited | 0.3319 | -12.89% | $446.40K | vs CDIO |
| IMDXInsight Molecular Diagnostics Inc. | 1.97 | +18.67% | $80.88M | vs CDIO |
| ICCCImmuCell Corporation | 10.92 | -2.41% | $99.28M | vs CDIO |
| NNNNAnbio Biotechnology Class A | 3.32 | -9.04% | $145.72M | vs CDIO |